Carterra: High Throughput Antibody Screening & Characterization

“We are pleased to have been a Key Opinion Leader (KOL) during the development of this fantastic parallel 48-channel SPR platform. The Carterra Vega will enable us to screen larger libraries faster and allow our researchers to run a greater number of screening and characterization projects, increasing our labs’ efficiency.”

Please visit our website for more information on this topic.

Antibodies selected from our libraries have high affinities and developability properties, as good as, or better, than clinical antibodies on the market, saving you time and money during development.

60% of antibodies selected directly from our Generation 3 libraries have affinities below 10nM; 20% have affinities in the subnanomolar range; and our best affinity antibody to date is 13 pM

After selection we use the machine learning module of AbXtract to group selected antibodies into as many as 1,000 distinctive clusters, providing antibodies against a wide variety of target epitopes

Over 80% of antibodies from our Generation 3 Platform have no measurable biophysical liabilities, with all tested to date behaving as well as, or better, than the best therapeutic antibodies.

AlpVHHs® contains other products and information you need, so please check it out.

To empower discovery at your site, we equip you with our integrated, state-of-the-art, antibody discovery platform, including exclusive libraries, vectors, protocols and extensive training.

All our libraries are provided as exclusive assets, with HCDR3 donors used once and other CDRs reassembled for each library, making the antibody diversity yours alone to mine, and not shared with others.

In addition to in-house designs, we create custom libraries, modifying scaffolds, tags, vectors or excluded liabilities. When you need more hands, let us conduct discovery using your exclusive library.

Our terms eliminate complexities typically seen in platform transfers. We recognize each company is unique, and have successfully tailored structures to meet each partner’s needs.

For more information, please visit Antibody Discovery Platform.